Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Trial Data
  5. Trial Initiation

Trial Initiation

Thumbnail
May 06, 2022

Anthos goes pivotal as Novartis and Pfizer look on

Thumbnail
May 04, 2022

Pfizer keeps pushing its inflammation pipeline

Article image
Vantage logo
April 29, 2022

Abbvie scraps cystic fibrosis triplet

Article image
Vantage logo
April 21, 2022

Jumping aboard the Claudin18.2 bandwagon

Article image
Vantage logo
March 25, 2022

Moderna needs to dispel doubts about its post-Covid strategy

Article image
Vantage logo
March 24, 2022

The year the regulators meet the microbiome

With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.

Article image
Vantage logo
March 15, 2022

Bridgebio looks to lead limb girdle pipeline

Article image
Vantage logo
February 24, 2022

As off-the-shelf cell therapies struggle Allogene plays on

Article image
Vantage logo
February 03, 2022

A year of Tigit (and Alzheimer’s) for Roche

With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.

Article image
Vantage logo
January 27, 2022

Galvani finally enters the clinic

Article image
Vantage logo
November 12, 2021

Astra presses on with bispecifics

Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.